Pfizer Inc. said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment